Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Stock Information for Apollomics Inc.

Loading

Please wait while we load your information from QuoteMedia.